Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) open the trading on Wednesday, with great promise as it jumped 6.20% to $248.79, before settling in for the price of $234.27 at the close. Taking a more long-term approach, ALNY posted a 52-week range of $141.98-$304.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 97.61%. Meanwhile, its Annual Earning per share during the time was 14.18%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 43.95%. This publicly-traded company’s shares outstanding now amounts to $128.98 million, simultaneously with a float of $127.95 million. The organization now has a market capitalization sitting at $32.09 billion. At the time of writing, stock’s 50-day Moving Average stood at $273.83, while the 200-day Moving Average is $211.50.
Alnylam Pharmaceuticals Inc (ALNY) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Alnylam Pharmaceuticals Inc’s current insider ownership accounts for 0.80%, in contrast to 96.58% institutional ownership. According to the most recent insider trade that took place on Aug 20 ’24, this organization’s Chief Executive Officer sold 15,000 shares at the rate of 280.00, making the entire transaction reach 4,200,000 in total value, affecting insider ownership by 73,441.
Alnylam Pharmaceuticals Inc (ALNY) Earnings and Revenue Records
Alnylam Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 43.95% and is forecasted to reach -1.08 in the upcoming year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Let’s observe the current performance indicators for Alnylam Pharmaceuticals Inc (ALNY). It’s Quick Ratio in the last reported quarter now stands at 2.69. The Stock has managed to achieve an average true range (ATR) of 9.94. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 15.32. Similarly, its price to free cash flow for trailing twelve months is now 1998.08.
In the same vein, ALNY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.62, a figure that is expected to reach -0.59 in the next quarter, and analysts are predicting that it will be -1.08 at the market close of one year from today.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
[Alnylam Pharmaceuticals Inc, ALNY] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 15.14% While, its Average True Range was 10.64.
Raw Stochastic average of Alnylam Pharmaceuticals Inc (ALNY) in the period of the previous 100 days is set at 25.40%, which indicates a major fall in contrast to 33.38% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 54.85% that was higher than 40.35% volatility it exhibited in the past 100-days period.
